Want to see FR:ALVIO full AI Analyst Report?
Top Page
Valerio Therapeutics
(ALVIO)
Select Model
Select Model
Rating:53Neutral
Price Target:
€0.86
▲(1331.67% Upside)
Action:Reiterated
Date:07/28/26
The score is anchored by improving 2025 financial execution (revenue rebound and positive operating/free cash flow) but is held back by significant balance-sheet risk (high leverage and recent equity instability) and continued net losses. Technically, the stock shows strong trend momentum with the price above all major moving averages, while valuation remains constrained by the negative P/E and no dividend yield data.
Positive Factors
Revenue rebound
The sharp revenue rebound indicates improved activity in the company’s development programs and provides a stronger base for future partnering or financing discussions, although the absolute revenue level remains modest for a clinical-stage biotechnology business.
Negative Factors
Persistent net losses
Continued net losses show that the company has not yet established sustainable earnings power. Ongoing oncology development costs may keep the business dependent on financing or partnering proceeds until a program generates larger recurring economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp revenue rebound indicates improved activity in the company’s development programs and provides a stronger base for future partnering or financing discussions, although the absolute revenue level remains modest for a clinical-stage biotechnology business.
Read all positive factors
Valerio Therapeutics (ALVIO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€408.11M
Dividend YieldN/A
Average Volume (3M)1.44M
Price to Earnings (P/E)―
Beta (1Y)-0.61
Revenue Growth43.50%
EPS Growth88.16%
CountryFR
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding567,668,640
10 Day Avg. Volume1,017,858
30 Day Avg. Volume1,435,255
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valerio Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on...
How the Company Makes Money
As a clinical-stage biotechnology company, Valerio Therapeutics’ monetization primarily depends on external financing and potential partnering economics tied to its drug-development programs. The company generally generates cash through (1) capita...
Valerio Therapeutics Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
24
Negative
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.57M | 1.79M | 1.80M | 1.44M | 4.06M |
| Gross Profit | 1.73M | 1.28M | 1.27M | 929.00K | 3.69M |
| EBITDA | 542.00K | -12.06M | -18.44M | -17.04M | -5.86M |
| Net Income | -4.90M | -23.93M | -20.34M | -19.56M | -5.94M |
Balance Sheet | |||||
| Total Assets | 15.23M | 17.93M | 35.27M | 43.09M | 53.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 1.18M | 6.82M | 14.59M | 17.89M |
| Total Debt | 7.61M | 13.44M | 9.00M | 10.09M | 9.94M |
| Total Liabilities | 13.16M | 26.19M | 20.47M | 20.82M | 20.12M |
| Stockholders Equity | 2.08M | -8.93M | 14.80M | 22.27M | 32.94M |
Cash Flow | |||||
| Free Cash Flow | 521.00K | -12.78M | -18.78M | -9.93M | -8.71M |
| Operating Cash Flow | 1.84M | -12.46M | -18.60M | -9.44M | -8.57M |
| Investing Cash Flow | -1.16M | -1.39M | -177.00K | -409.00K | -66.00K |
| Financing Cash Flow | -774.00K | 4.21M | 10.76M | 6.46M | 11.98M |
Valerio Therapeutics Technical Analysis
Neutral
0.06
Price Trends
0.69
Positive
0.44
Positive
0.29
Positive
Market Momentum
<0.01
Positive
48.66
Neutral
35.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVIO, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.69, and below the 200-day MA of 0.29, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.66 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALVIO.
Valerio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | €408.11M | -22.27 | 139.11% | ― | 43.50% | 88.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €185.20M | -2.90 | 593.93% | ― | -77.92% | 11.11% | |
49 Neutral | €26.28M | -1.37 | 42.20% | ― | -99.93% | 44.53% | |
48 Neutral | €198.17M | -4.86 | -94.14% | ― | -5.98% | -8.67% | |
47 Neutral | €245.16M | -3.39 | -63.53% | ― | 291.43% | 12.24% | |
43 Neutral | €67.90M | -1.63 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
FR:ALVIO
Valerio Therapeutics
0.71
0.65
1076.67%
FR:IPH
Innate Pharma SA
1.59
-0.18
-9.94%
FR:TNG
Transgene
0.88
-0.27
-23.30%
FR:OSE
OSE Immunotherapeutics SA
2.75
-3.28
-54.39%
FR:SIGHT
GenSight Biologics SA
0.11
-0.04
-27.92%
FR:ALCLS
Cellectis SA
2.74
-0.05
-1.86%
Valerio Therapeutics Corporate Events
Valerio Therapeutics to Acquire Etherna and Raises €40.25m in PIPE to Fund RNA Push
Aug 24, 2026
Valerio Therapeutics has signed a definitive agreement to acquire 100% of Etherna Immunotherapies NV for an enterprise value of €30 million, to be paid in cash and shares. The deal is intended to merge Etherna’s RNA and lipid nanoparti...
Valerio Therapeutics Nears Signing of €30 Million Etherna Acquisition
Aug 17, 2026
Valerio Therapeutics has provided an update on its project to acquire 100% of Etherna Immunotherapies NV, following a binding offer made on July 1, 2026 that valued the target at an enterprise value of €30 million. The companies had initiall...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.